The treatment outcome and impact on blood transfusion demand of Peg-interferon/ribavirin in thalassemic patients with chronic hepatitis C

The treatment outcome and impact on blood transfusion demand of Peg-interferon/ribavirin in thalassemic patients with chronic hepatitis C

Hepatitis C virus (HCV) prevails in patients with thalassemia. We aimed to investigate the efficacy, safety, and impact on red blood cells (RBC) transfusion demand of pegylated interferon (Peg-IFN)/ribavirin therapy in thalassemic patients with HCV. Methods: This retrospective study included 18 thal...

Full description

Bibliographic Details
Main Authors: Po-Cheng Liang, Pei-Chin Lin, Ching-I. Huang, Chung-Feng Huang, Ming-Lun Yeh, Yu-Sheng Zeng, Wan-Yi Hsu, Ming-Yen Hsieh, Zu-Yau Lin, Shinn-Cherng Chen, Jee-Fu Huang, Chia-Yen Dai, Wan-Long Chuang, Shyh-Shin Chiou, Ming-Lung Yu
Format: Article
Language:English
Published: Elsevier 2018-01-01
Series:Journal of the Formosan Medical Association
Subjects:
Hepatitis C
Thalassemia
Interferon
Interleukin-28B
Anemia
Blood transfusion
Online Access:http://www.sciencedirect.com/science/article/pii/S0929664616304740

Internet

http://www.sciencedirect.com/science/article/pii/S0929664616304740

Similar Items